Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for Wet AMD

Kodiak Sciences announced that updated data from the clinical development program for its investigational therapy KSI-301 will be presented at The Retina Society Annual Meeting on September 15 in London.

“Developing intravitreal medicines with meaningfully differentiated durability has been Kodiak’s objective since our founding one decade ago. Kodiak’s announcement at this weekend’s Retina Society Annual Meeting takes us another step closer to providing a transformative new therapeutic option to patients. I believe KSI-301 has the potential to be a first-line anti-VEGF agent for patients suffering from retinal vascular diseases,” Victor Perlroth, MD, Chief Executive Officer of Kodiak Sciences, said in a company news release. “We are pleased to have Dr. David Brown present the emerging durability data from our ongoing phase 1b study of KSI-301 with the community on September 15. His presentation represents a key early look into KSI-301’s durability in advance of a more detailed data presentation planned for the American Academy of Ophthalmology Retina Subspecialty Day on October 11.”

Details of the presentation are as follows:

Oral Presentation: Novel Anti-VEGF Antibody Biopolymer Conjugate KSI-301 with Potential for Extended Durability in Retinal Vascular Diseases: Late-Breaking Results from a Phase 1b Study in Patients with wAMD, DME and RVO

Presenter: David M. Brown, MD, FACS — Clinical Professor of Ophthalmology at Baylor College of Medicine, and Vice-Chair for Research at the Blanton Eye Institute, Houston Methodist Hospital; Partner at Retina Consultants of Houston, Houston, TX

Presentation date and time: Sunday, September 15, 2019 – 11:08 am BST

The slide presentation will be available on the Kodiak Investor Relations website at http://ir.kodiak.com/ at the time of the presentation.